It is GSK1210151A generally well accepted that liposomes containing natural phospholipids, triglycerides, and cholesterol should not present any risk of antigenicity, presumably due to their similarities with biological membranes [21]. Natural phospholipids such as phosphatidylcholines with neutral net charge in physiologic conditions are used to construct liposomes that closely resemble biologic membranes. This type of liposomes made of naturally occurring phospholipids is generally considered safe for parenteral use. Certain types of liposomes may Inhibitors,research,lifescience,medical cause extensive tissue damage. Particularly, those composed of lecithin-cholesterol-dicetyl

phosphate or lecithin-cholesterol-stearylamine have been reported to cause widespread tissue necrosis, epilepsy, and some deaths due to respiratory failure immediately after injection in mice whereas liposomes composed of phosphatidylcholine cholesterol-phosphatidic acid, or dipalmitoyl phosphatidylcholine only, produced minimal morphological

changes and by the sixth day post-injection; the histopathology was limited to the mechanical trauma Inhibitors,research,lifescience,medical caused by the injection [22]. Published studies with LipoSpheres containing tristearin and egg phosphatidylcholine in rats have shown no evidence of nerve damage and very little perineural inflammation or foreign body response [23]. Similarly, multilamellar vesicles Inhibitors,research,lifescience,medical liposomes made of egg yolk phosphatidylcholine and cholesterol-containing bupivacaine have not been shown to produce histologic lesions on peripheral nerves after either brachial plexus injection [24] or intracerebral administration [25]. Malinovsky et al. has found that the incorporation of bupivacaine into multivesicular liposomes devoid of phosphatidylcholine hydrolysis products or oxidation Inhibitors,research,lifescience,medical compounds produce spinal cord histopathologic changes not significantly Inhibitors,research,lifescience,medical different from bupivacaine solution after intracisternal administration in rabbits [26]. More recently, drug carriers such as cyclodextrins have shown that the inclusion of bupivacaine 0.5% in hydroxypropyl-[beta]-cyclodextrin in equal amounts produced minimal histological alterations of the rat

sciatic nerve 48 hours after intraneural injection [27]. During Sodium butyrate an investigation of the pharmacological activity, cytotoxicity and local effects of ropivacaine 0.125%, 0.25%, and 0.5% concentrations encapsulated into large unilamellar vesicles composed of egg phosphatidylcholine, cholesterol, and alpha-tocopherol (4:3:0.07, mole %) compared with drug solution showed that there was no morphological tissue changes in the area of injection and sparse inflammatory cells were observed in only one of the animals treated with plain solution or ropivacaine at 0.5% [28]. In sciatic-nerve block experiments in rats, Söderberg et al. [29] showed that after two weeks following perineural injection of various formulations containing 2.0%, 10%, 20%, 60%, or 80% of lidocaine:prilocaine 1:1 mixtures in medium chain triglycerides compared to saline, vehicle, 2.